NL-OMON30521招募中不适用
Risk factors for non-melanoma skin cancer (NMSC) 1. Skin carcinoma progression analyzed by genome-wide gene expression profiling and mimicked by validated organotypic in vitro human skin cancer models; towards an integrative system-biology approach and an in vitro screening method for targeted skin cancer therapies. 2.Genetic and environmental risk factors for the development of skin cancer in organ-transplant recipients. - Risk factors for non-melanoma skin cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational invasive
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Organ-transplant patients and immunocompetent persons with and without skin cancer.
排除标准
- •No consent of the patient.
研究者
相似试验
已完成
不适用
A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC)Non-melanoma Skin CancerNCT03693937Sensus Healthcare776
进行中（未招募）
1 期
Risk of Skin Cancer on Skin Areas Treated with Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%EUCTR2012-003112-31-DEEO Pharma A/S480
进行中（未招募）
1 期
Risk of Skin Cancer on Skin Areas Treated with Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%EUCTR2012-003112-31-FREO Pharma A/S480
进行中（未招募）
不适用
Risk of Skin Cancer on Skin Areas Treated with Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%EUCTR2012-003112-31-GBEO Pharma A/S480
进行中（未招募）
不适用
Prevention of skin cancer in high risk patients after conversion a to Sirolimus-based immunosuppressive - PROSKIMedical condition: renal transplant-patients at high-risk for skin cancerTransplant recipients have a high risk to develop skin malignancies. This depends on the immunosuppressive drugs and is related to the dosage. This study assesses whether a switch to a SRL-immunosuppressive therapy decreases the incidence/reoccurence of skin neoplasm.EUCTR2006-001528-38-DECharité Universitätsmedizin Berlin